Výsledky vyhledávání - Toru Ishikawa
- Zobrazuji výsledky 1 - 20 z 38
- Přejít na další stránku
-
1
-
2
-
3
-
4
SUN-366 The Optimal Cutoff Value for Basal Plasma Aldosterone Concentration Suspected as Primary Aldosteronism Distributed According to Aldosterone-Renin Ratio and Confirmatory Tes... Autor Toru, Ishikawa, Watanabe, Daisuke, Yatabe, Midori, Yatabe, Junichi, Morimoto, Satoshi, Ichihara, Atsuhiro
Vydáno 2019Text -
5
Erratum to: Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis Autor Hidenori Toyoda, Takashi Kumada, Toshifumi Tada, Koichi Takaguchi, Toru Ishikawa, Kunihiko Tsuji, Mikio Zeniya, Etsuko Iio, Yasuhito Tanaka
Vydáno 2016Errata/Corrigenda -
6
-
7
Role of hepatic resection in patients with intermediate‐stage hepatocellular carcinoma: A multicenter study from Japan Autor Toshifumi Tada, Takashi Kumada, Hidenori Toyoda, Kunihiko Tsuji, Atsushi Hiraoka, Ei Itobayashi, Kazuhiro Nouso, Kazuya Kariyama, Toru Ishikawa, Masashi Hirooka, Yoichi Hiasa
Vydáno 2017Artigo -
8
Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies Autor Kazuya Kariyama, Kazuhiro Nouso, Akiko Wakuta, Ayano Oonishi, Hidenori Toyoda, Toshifumi Tada, Atsushi Hiraoka, Kunihiko Tsuji, Ei Itobayashi, Toru Ishikawa, Koichi Takaguchi, Akemi Tsutsui, Noritomo Shimada, Takashi Kumada
Vydáno 2019Artigo -
9
Transition in the etiology of liver cirrhosis in Japan: a nationwide survey Autor Hirayuki Enomoto, Yoshiyuki Ueno, Yoichi Hiasa, Hiroki Nishikawa, Shuhei Hige, Yasuhiro Takikawa, Makiko Taniai, Toru Ishikawa, Kohichiroh Yasui, Akinobu Takaki, Koichi Takaguchi, Akio Ido, Masayuki Kurosaki, Tatsuya Kanto, Shuhei Nishiguchi
Vydáno 2019Artigo -
10
The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan Autor Hirayuki Enomoto, Yoshiyuki Ueno, Yoichi Hiasa, Hiroki Nishikawa, Shuhei Hige, Yasuhiro Takikawa, Makiko Taniai, Toru Ishikawa, Kohichiroh Yasui, Akinobu Takaki, Koichi Takaguchi, Akio Ido, Masayuki Kurosaki, Tatsuya Kanto, Shuhei Nishiguchi
Vydáno 2020Artigo -
11
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis Autor Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, Akiko Wakuta, Ayano Oonishi, Teiji Kuzuya, Hidenori Toyoda, Toshifumi Tada, Kunihiko Tsuji, Ei Itobayashi, Toru Ishikawa, Koichi Takaguchi, Akemi Tsutsui, Noritomo Shimada, Masatoshi Kudo, Takashi Kumada
Vydáno 2020Artigo -
12
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pu... Autor Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo, Masashi Hirooka, Kunihiko Tsuji, Ei Itobayashi, Kazuya Kariyama, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Kouji Joko, Hideki Kawasaki, Yoichi Hiasa, Kojiro Michitaka
Vydáno 2017Artigo -
13
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis Autor Atsushi Hiraoka, Takashi Kumada, Kunihiko Tsuji, Koichi Takaguchi, Ei Itobayashi, Kazuya Kariyama, Hironori Ochi, Kazuto Tajiri, Masashi Hirooka, Noritomo Shimada, Toru Ishikawa, Yoshihiko Tachi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Kouji Joko, Yoichi Hiasa, Kojiro Michitaka, Masatoshi Kudo
Vydáno 2018Artigo -
14
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis Autor Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, Koichi Takaguchi, Ei Itobayashi, Noritomo Shimada, Kazuto Tajiri, Kunihiko Tsuji, Toru Ishikawa, Hironori Ochi, Masashi Hirooka, Akemi Tsutsui, Hiroshi Shibata, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Kouji Joko, Yoichi Hiasa, Kojiro Michitaka
Vydáno 2018Artigo -
15
Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures Autor Hisashi Hidaka, Masayuki Kurosaki, Hironori Tanaka, Masatoshi Kudo, Seigo Abiru, Takumi Igura, Toru Ishikawa, Masataka Seike, Takayuki Katsube, Toshimitsu Ochiai, Kazuhiro Kimura, Takahiro Fukuhara, Takeshi Kano, Tsutae Den Nagata, Katsuaki Tanaka, Mineo Kurokawa, Kazuhide Yamamoto, Yukio Osaki, Namiki Izumi, Michio Imawari
Vydáno 2018Artigo -
16
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis Autor Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, Koichi Takaguchi, Masanori Atsukawa, Ei Itobayashi, Kunihiko Tsuji, Kazuto Tajiri, Masashi Hirooka, Noritomo Shimada, Hiroshi Shibata, Toru Ishikawa, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Akemi Tsutsui, Norio Itokawa, Michitaka Imai, Kouji Joko, Yoichi Hiasa, Kojiro Michitaka
Vydáno 2018Artigo -
17
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study Autor Margherita Rimini, Shigeo Shimose, Sara Lonardi, Toshifumi Tada, Gianluca Masi, Hideki Iwamoto, Eleonora Lai, Valentina Burgio, Atsushi Hiraoka, Toru Ishikawa, Caterina Soldà, Tomotake Shirono, Caterina Vivaldi, Koichi Takaguchi, Noritomo Shimada, Giorgio Astara, Hironori Koga, Kazuhiro Nouso, Kouji Joko, Takuji Torimura, Yoichi Hiasa, Francesca Salani, Mario Scartozzi, Stefano Cascinu, Andrea Casadei‐Gardini
Vydáno 2021Artigo -
18
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis Autor Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Korenobu Hayama, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Kojiro Michitaka, Masatoshi Kudo
Vydáno 2019Artigo -
19
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-... Autor Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, Toru Ishikawa, Yoshitaka Inaba, Naoki Morimoto, Hiroshi Aikata, Nobukazu Tanabe, Yoshiyuki Wada, Yasuteru Kondo, Masahiro Tsuda, Kazuhiko Nakao, Takanori Ito, Tetsuya Hosaka, Yusuke Kawamura, Teiji Kuzuya, Shunsuke Nojiri, Chikara Ogawa, Hironori Koga, Keisuke Hino, Masafumi Ikeda, Michihisa Moriguchi, Takashi Hisai, Kenichi Yoshimura, Junji Furuse, Yasuaki Arai
Vydáno 2023Artigo -
20
Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib Autor Atsushi Hiraoka, Takashi Kumada, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Keisuke Yokohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Korenobu Hayama, Taeang Arai, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Kojiro Michitaka, Masatoshi Kudo
Vydáno 2019Artigo
Vyhledávací nástroje:
Související témata
Internal medicine
Medicine
Hepatocellular carcinoma
Gastroenterology
Oncology
Cancer
Lenvatinib
Sorafenib
Atezolizumab
Bevacizumab
Chemotherapy
Immunotherapy
Biology
Confidence interval
Hazard ratio
Nivolumab
Adverse effect
Paleontology
Proportional hazards model
Stage (stratigraphy)
Carcinoma
Liver function
Chemistry
Disease
Etiology
Hepatology
Multivariate analysis
Surgery
Biochemistry
Cell biology